Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Evaluating the role of p38 MAP kinase in growth of Werner syndrome fibroblasts.

Davis T, Bachler MA, Wyllie FS, Bagley MC, Kipling D.

Ann N Y Acad Sci. 2010 Jun;1197:45-8. doi: 10.1111/j.1749-6632.2010.05195.x. Review.

PMID:
20536832
2.

The role of cellular senescence in Werner syndrome: toward therapeutic intervention in human premature aging.

Davis T, Wyllie FS, Rokicki MJ, Bagley MC, Kipling D.

Ann N Y Acad Sci. 2007 Apr;1100:455-69. Review.

PMID:
17460211
3.
4.

Telomere-based proliferative lifespan barriers in Werner-syndrome fibroblasts involve both p53-dependent and p53-independent mechanisms.

Davis T, Singhrao SK, Wyllie FS, Haughton MF, Smith PJ, Wiltshire M, Wynford-Thomas D, Jones CJ, Faragher RG, Kipling D.

J Cell Sci. 2003 Apr 1;116(Pt 7):1349-57.

5.

An analysis of replicative senescence in dermal fibroblasts derived from chronic leg wounds predicts that telomerase therapy would fail to reverse their disease-specific cellular and proteolytic phenotype.

Stephens P, Cook H, Hilton J, Jones CJ, Haughton MF, Wyllie FS, Skinner JW, Harding KG, Kipling D, Thomas DW.

Exp Cell Res. 2003 Feb 1;283(1):22-35.

PMID:
12565817
6.

Evidence for a telomere-independent "clock" limiting RAS oncogene-driven proliferation of human thyroid epithelial cells.

Jones CJ, Kipling D, Morris M, Hepburn P, Skinner J, Bounacer A, Wyllie FS, Ivan M, Bartek J, Wynford-Thomas D, Bond JA.

Mol Cell Biol. 2000 Aug;20(15):5690-9.

7.

Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts.

Wyllie FS, Jones CJ, Skinner JW, Haughton MF, Wallis C, Wynford-Thomas D, Faragher RG, Kipling D.

Nat Genet. 2000 Jan;24(1):16-7. No abstract available.

PMID:
10615119
8.

p53-Dependent growth arrest and altered p53-immunoreactivity following metabolic labelling with 32P ortho-phosphate in human fibroblasts.

Bond JA, Webley K, Wyllie FS, Jones CJ, Craig A, Hupp T, Wynford-Thomas D.

Oncogene. 1999 Jun 24;18(25):3788-92.

9.

Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53.

Wyllie FS, Haughton MF, Rowson JM, Wynford-Thomas D.

Br J Cancer. 1999 Mar;79(7-8):1111-20.

10.

Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis.

Bond JA, Haughton MF, Rowson JM, Smith PJ, Gire V, Wynford-Thomas D, Wyllie FS.

Mol Cell Biol. 1999 Apr;19(4):3103-14.

11.

Segregational fidelity of chromosomes in human thyroid tumour cells.

Parry EM, Ulucan H, Wyllie FS, Wynford-Thomas D, Parry JM.

Chromosoma. 1998 Dec;107(6-7):491-7.

PMID:
9914382
12.

Dissociation of telomere dynamics from telomerase activity in human thyroid cancer cells.

Jones CJ, Soley A, Skinner JW, Gupta J, Haughton MF, Wyllie FS, Schlumberger M, Bacchetti S, Wynford-Thomas D.

Exp Cell Res. 1998 May 1;240(2):333-9.

PMID:
9597006
13.

The tumour suppressor gene p53 as a regulator of proliferative life-span and tumour progression.

Wynford-Thomas D, Jones CJ, Wyllie FS.

Biol Signals. 1996 May-Jun;5(3):139-53. Review.

PMID:
8864059
14.

S phase cell-cycle arrest following DNA damage is independent of the p53/p21(WAF1) signalling pathway.

Wyllie FS, Haughton MF, Bond JA, Rowson JM, Jones CJ, Wynford-Thomas D.

Oncogene. 1996 Mar 7;12(5):1077-82.

PMID:
8649799
15.

High frequency deletion of the tumour suppressor gene P16INK4a (MTS1) in human thyroid cancer cell lines.

Jones CJ, Shaw JJ, Wyllie FS, Gaillard N, Schlumberger M, Wynford-Thomas D.

Mol Cell Endocrinol. 1996 Jan 15;116(1):115-9.

PMID:
8822272
16.

Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1.

Bond JA, Blaydes JP, Rowson J, Haughton MF, Smith JR, Wynford-Thomas D, Wyllie FS.

Cancer Res. 1995 Jun 1;55(11):2404-9.

17.

Does telomere shortening drive selection for p53 mutation in human cancer?

Wynford-Thomas D, Bond JA, Wyllie FS, Jones CJ.

Mol Carcinog. 1995 Mar;12(3):119-23. Review. No abstract available.

PMID:
7893364
18.

Interaction between p53 and TGF beta 1 in control of epithelial cell proliferation.

Blaydes JP, Schlumberger M, Wynford-Thomas D, Wyllie FS.

Oncogene. 1995 Jan 19;10(2):307-17.

PMID:
7838530
19.

Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells.

Wyllie FS, Haughton MF, Blaydes JP, Schlumberger M, Wynford-Thomas D.

Oncogene. 1995 Jan 5;10(1):49-59.

PMID:
7529918
20.

Escape from senescence in human diploid fibroblasts induced directly by mutant p53.

Bond JA, Wyllie FS, Wynford-Thomas D.

Oncogene. 1994 Jul;9(7):1885-9.

PMID:
8208534
21.

In vitro reconstruction of tumour initiation in a human epithelium.

Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford-Thomas D.

Oncogene. 1994 Jan;9(1):281-90.

PMID:
8302590
22.

A variant epithelial sub-population in normal thyroid with high proliferative capacity in vitro.

Bond JA, Wyllie FS, Ivan M, Dawson T, Wynford-Thomas D.

Mol Cell Endocrinol. 1993 Jun;93(2):175-83.

PMID:
7688704
23.

Direct growth stimulation of normal human epithelial cells by mutant p53.

Wyllie FS, Lemoine NR, Barton CM, Dawson T, Bond J, Wynford-Thomas D.

Mol Carcinog. 1993;7(2):83-8.

PMID:
8457292
24.

A phenotypically and karyotypically stable human thyroid epithelial line conditionally immortalized by SV40 large T antigen.

Wyllie FS, Bond JA, Dawson T, White D, Davies R, Wynford-Thomas D.

Cancer Res. 1992 May 15;52(10):2938-45.

25.

Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.

Wright PA, Lemoine NR, Goretzki PE, Wyllie FS, Bond J, Hughes C, Röher HD, Williams ED, Wynford-Thomas D.

Oncogene. 1991 Sep;6(9):1693-7.

PMID:
1923534
26.
27.

Correlated abnormalities of transforming growth factor-beta 1 response and p53 expression in thyroid epithelial cell transformation.

Wyllie FS, Dawson T, Bond JA, Goretzki P, Game S, Prime S, Wynford-Thomas D.

Mol Cell Endocrinol. 1991 Apr;76(1-3):13-21.

PMID:
1820969
28.

Partial transformation of human thyroid epithelial cells by mutant Ha-ras oncogene.

Lemoine NR, Staddon S, Bond J, Wyllie FS, Shaw JJ, Wynford-Thomas D.

Oncogene. 1990 Dec;5(12):1833-7.

PMID:
1704496
29.

Conditional immortalization of human thyroid epithelial cells: a tool for analysis of oncogene action.

Wynford-Thomas D, Bond JA, Wyllie FS, Burns JS, Williams ED, Jones T, Sheer D, Lemoine NR.

Mol Cell Biol. 1990 Oct;10(10):5365-77.

30.

Immunocytochemically detectable TGF-beta associated with malignancy in thyroid epithelial neoplasia.

Jasani B, Wyllie FS, Wright PA, Lemoine NR, Williams ED, Wynford-Thomas D.

Growth Factors. 1990;2(2-3):149-55.

PMID:
2187493
31.

Absence of abnormalities of the c-erbB-1 and c-erbB-2 proto-oncogenes in human thyroid neoplasia.

Lemoine NR, Wyllie FS, Lillehaug JR, Staddon SL, Hughes CM, Aasland R, Shaw J, Varhaug JE, Brown CL, Gullick WJ, et al.

Eur J Cancer. 1990;26(7):777-9.

PMID:
2145893
32.

Structure and expression of nuclear oncogenes in multi-stage thyroid tumorigenesis.

Wyllie FS, Lemoine NR, Williams ED, Wynford-Thomas D.

Br J Cancer. 1989 Oct;60(4):561-5.

33.

Papillary and follicular thyroid carcinomas show a different pattern of ras oncogene mutation.

Wright PA, Lemoine NR, Mayall ES, Wyllie FS, Hughes D, Williams ED, Wynford-Thomas D.

Br J Cancer. 1989 Oct;60(4):576-7. No abstract available.

34.

High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.

Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D.

Oncogene. 1989 Feb;4(2):159-64.

PMID:
2648253
35.

Activated ras oncogenes in human thyroid cancers.

Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, Thurston V, Williams ED, Wynford-Thomas D.

Cancer Res. 1988 Aug 15;48(16):4459-63.

36.

N-myc expression in neoplasia of human thyroid C-cells.

Boultwood J, Wyllie FS, Williams ED, Wynford-Thomas D.

Cancer Res. 1988 Jul 15;48(14):4073-7.

37.

RFLP for the human erb-A beta locus.

Wyllie FS, Lazarou LP, Wynford-Thomas D.

Nucleic Acids Res. 1988 Jun 10;16(11):5224. No abstract available.

38.

Ha-ras restriction fragment length polymorphisms in colorectal cancer.

Wyllie FS, Wynford-Thomas V, Lemoine NR, Williams GT, Williams ED, Wynford-Thomas D.

Br J Cancer. 1988 Feb;57(2):135-8.

Supplemental Content

Loading ...
Support Center